Shares dropped 9.6% as investors reacted negatively to the company’s cautious outlook and clear indication of a continued trough in free cash flow due to a softer release slate, restructuring costs, and the ongoing transformation. The combination of significant deceleration in new releases and short-term financial underperformance overshadowed some stable margin metrics and solid back catalog results.